Biomet Goes Solo in Europe

Biomet is buying out Merck's share of their successful orthopedics joint venture in Europe. Although Biomet ran into few, if any, major disagreements with Merck over the life of the joint venture, the joint ownership did sometimes put Biomet in a difficult position. Potential acquisitions all had to be viewed for their potential financial implications on Merck. Thus, one major benefit of the buyout, in addition to giving Biomet more efficient European operations, is that it frees the company to do more acquisitions.

Six years ago, seeking to boost sales and build a more robust European business, Warsaw, IN-based Biomet Inc. created a joint venture with German pharmaceutical manufacturer Merck KGAA . [See Deal] Each company would leverage its existing offerings and operations with the complementary offerings of its partner. But the very success of the joint effort led to its demise, at least as a collaboration, with Biomet announcing in December that it has bought out Merck and will run the continued operations on its own.

Biomet and Merck began their joint venture, called Biomet-Merck, in February of 1998. Biomet brought its European orthopedics operations to...

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.